These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36427348)

  • 1. Chronic graft-vs-host disease: Current understanding of disease and treatment landscape.
    Flavin B
    J Manag Care Spec Pharm; 2022 Dec; 28(12-b Suppl):S2-S12. PubMed ID: 36427348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care.
    Cazeau N; Rodriguez S
    Clin J Oncol Nurs; 2023 May; 27(3):259-265. PubMed ID: 37267484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.
    Wolff D; Fatobene G; Rocha V; Kröger N; Flowers ME
    Bone Marrow Transplant; 2021 Sep; 56(9):2079-2087. PubMed ID: 34218265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
    Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
    JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
    Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
    Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
    Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
    Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
    Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
    Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
    Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis.
    Bachier CR; Aggarwal SK; Hennegan K; Milgroom A; Francis K; Dehipawala S; Rotta M
    Transplant Cell Ther; 2021 Jun; 27(6):504.e1-504.e6. PubMed ID: 34158154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
    Gonzalez RM; Pidala J
    Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of rituximab in chronic graft-versus-host disease.
    Bates JS; Engemann AM; Hammond JM
    Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review.
    Shahzad M; Chaudhary SG; Basit A; Thellman C; Rodriguez L; Abhyankar SH; McGuirk JP; Mushtaq MU
    Transpl Immunol; 2022 Feb; 70():101520. PubMed ID: 34952168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
    Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
    Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
    Jaglowski SM; Blazar BR
    Blood Adv; 2018 Aug; 2(15):2012-2019. PubMed ID: 30108109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
    Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
    Belina ME; Driscoll TA; Blanchard SK; Cardones AR
    Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.
    Baek DW; Cho HJ; Kim JH; Ahn JS; Kim HJ; Lim SN; Cheong JW; Kim SY; Lee HS; Won JH; Yhim HY; Sohn SK; Moon JH
    Cell Transplant; 2022; 31():9636897221113789. PubMed ID: 35861214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
    Elad S; Levitt M; M Y S
    Refuat Hapeh Vehashinayim (1993); 2008 Nov; 25(4):19-27, 72. PubMed ID: 19263864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.